Page last updated: 2024-11-05

phosphoric acid, trisodium salt

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Also known as sodium phosphate or tribasic sodium phosphate, this inorganic compound is a white solid that is soluble in water. It is a common food additive used as a buffering agent, emulsifier, and sequestering agent. It is also used in various industrial applications such as in detergents, fertilizers, and water treatment. Sodium phosphate is produced commercially by reacting phosphoric acid with sodium hydroxide. Its effects can be divided into those relevant to food and those relevant to health. In food, it can improve the texture, taste, and shelf life of various products. In the human body, sodium phosphate is important for maintaining electrolyte balance and bone health. It can be used to treat certain medical conditions such as constipation and electrolyte imbalances. Sodium phosphate is studied extensively to better understand its safety and efficacy as a food additive and medical treatment.'

Cross-References

ID SourceID
PubMed CID24243
CHEBI ID37583
MeSH IDM0044806

Synonyms (77)

Synonym
caswell no. 898
oakite
hsdb 583
nutrifos stp
trinatriumphosphat [german]
sodium phosphate (van)
einecs 231-509-8
sodium orthophosphate, tertiary
nsc 215202
epa pesticide chemical code 076406
emulsiphos 440/660
ccris 7086
sodium orthophosphate, tribasic
tertiary sodium phosphate
trinatriumphosphat
CHEBI:37583 ,
sodium phosphate tribasic
sodium phosphate (na3po4)
sodium phosphate, anhydrous
7601-54-9
trisodium orthophosphate
trisodium phosphate
sodium phosphate
tribasic sodium phosphate
phosphoric acid, trisodium salt
phosphoric acid trisodium salt
nsc-215202
sodium phosphate, 96%
sodium phosphate, tribasic (nf)
D09000
sodium phosphate (tribasic)
sodium phosphate,tribasic
ins-339(iii)
tribasic sodium-phosphate
e-339(iii)
FT-0650556
trisodium trihydrogen bis(phosphate)
monosodium phosphate disodium phosphate double salt
einecs 265-604-0
sx01tzo3qz ,
phosphoric acid, sodium salt (1:3)
ec 231-509-8
unii-sx01tzo3qz
68130-75-6
einecs 268-603-3
BP-30114
sodium phosphate,tribasic [vandf]
sodium phosphate, tribasic, anhydrous
sodium phosphate, tribasic [mi]
ins no.339(iii)
trisodium phosphate [hsdb]
sodium phosphate tribasic [who-dd]
sodium phosphate, tribasic anhydrous
sodium phosphate, tribasic, anhydrous [ii]
sodiumphosphate
sodium phophate
sodium monophosphate
RYFMWSXOAZQYPI-UHFFFAOYSA-K
tri-sodium phosphate
trisodium phosphate anhydrous
DTXSID2035223
mfcd00003510
AKOS028109702
sodium phosphate, saj first grade, >=97.0%
sodium phosphate, ar, >=95.5%
sodium phosphate tribasic, p.a., 97%
phosphoric acid, sodiumsalt (1:?)
sodium orthohosphate
Q409501
sodium phosphate, tribasic; sodium tertiary phosphate; tribasic sodium orthophosphate; tribasic sodium phosphate; trisodium orthophosphate
D78139
trisodium;phosphate
sodium;phosphoric acid
phosphoric acid, sodiumsalt
trisodium phosphate anhydrous nf/fcc grade
O0586
na3o4p

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"This study suggests that oral NaP is a safe agent in most patients for colonic cleansing, even when given using a 5-h regimen."( Safety profile of 5-h oral sodium phosphate regimen for colonoscopy cleansing: lack of clinically significant hypocalcemia or hypovolemia.
Huynh, T; Paterson, W; Vanner, S, 1995
)
0.29
" Safe use requires ensuring an adequate oral fluid intake during the preparation time and avoidance of use in patients with renal insufficiency."( Colonoscopy preparation in children: safety, efficacy, and tolerance of high- versus low-volume cleansing methods.
Briars, GL; Cleghorn, GJ; da Silva, MM; Patrick, MK; Shepherd, RW, 1997
)
0.3
" Adverse events were closely followed and recorded."( A novel tableted purgative for colonoscopic preparation: efficacy and safety comparisons with Colyte and Fleet Phospho-Soda.
Aronchick, CA; Bergman, G; Dufrayne, F; Lipshutz, WH; Wright, SH, 2000
)
0.31
" Although hypocalcemia (4 of 71), hypokalemia (18 of 68), and hyperphosphatemia (39 of 69) were observed in patients receiving the tablets, no adverse events occurred."( A novel tableted purgative for colonoscopic preparation: efficacy and safety comparisons with Colyte and Fleet Phospho-Soda.
Aronchick, CA; Bergman, G; Dufrayne, F; Lipshutz, WH; Wright, SH, 2000
)
0.31
"Based on the effectiveness, safety and tolerability profile of oral sodium phosphate solution in patients, it can be considered the preparation of choice before colonoscopy, since it allows a fast, effective and safe bowel cleansing in patients without contraindications."( Characterization of the safety, effectiveness and use of oral sodium phosphate.
Pou Fernández, JM; Rodríguez Muñoz, S; Sala Felis, T, 2001
)
0.31
" Safety assessments included recording of adverse events and changes in biochemical tests, electrocardiogram, and vital signs."( Efficacy and safety of sodium phosphate tablets compared with PEG solution in colon cleansing: two identically designed, randomized, controlled, parallel group, multicenter phase III trials.
Chasen, R; Choudhary, C; Kastenberg, D; Riff, D; Steinberg, S; Weiss, E; Wruble, L, 2001
)
0.31
" Adverse events were collected and evaluated."( Safety and efficacy of two reduced dosing regimens of sodium phosphate tablets for preparation prior to colonoscopy.
Chasen, R; Pochapin, MB; Rex, DK, 2002
)
0.31
" All patients were able to complete the assigned dose of tablets, and there were no deaths, serious adverse events or dropouts from the study."( Safety and efficacy of two reduced dosing regimens of sodium phosphate tablets for preparation prior to colonoscopy.
Chasen, R; Pochapin, MB; Rex, DK, 2002
)
0.31
"Oral sodium phosphate is well tolerated, is safe and provides bowel cleansing similar to that with a polyethylene glycol solution."( Efficacy and safety of oral sodium phosphate versus polyethylene glycol solution for bowel preparation for colonoscopy.
Rao, GV; Reddy, DN; Sriram, PV,
)
0.13
" Adverse events (mainly nausea/vomiting and abdominal pain) and deviations in laboratory values occurred more frequently in the NaP group."( A randomized, blinded, prospective trial to compare the safety and efficacy of three bowel-cleansing solutions for colonoscopy (HSG-01*).
Albrecht, U; Dehe, M; Ell, C; Fischbach, W; Keller, R; Mayer, G; Schneider, B; Schuette, W, 2003
)
0.32
"To compare the incidence of peri-procedure adverse events in patients undergoing colon cleansing with sodium phosphate tablets or polyethylene glycol solution prior to colonoscopy with propofol-based sedation."( Safety of sodium phosphate tablets in patients receiving propofol-based sedation for colonoscopy.
Eschinger, EJ; Kastenberg, DM; Katz, LC; Littman, JJ; Meyer, K; Milman, PJ,
)
0.13
" Study data and anesthesia records were reviewed for peri-procedure hemodynamic, cardiac, and pulmonary adverse events as well as the need for hospital admission."( Safety of sodium phosphate tablets in patients receiving propofol-based sedation for colonoscopy.
Eschinger, EJ; Kastenberg, DM; Katz, LC; Littman, JJ; Meyer, K; Milman, PJ,
)
0.13
"Peri-procedure adverse events occurred rarely and with no increased frequency in patients using the sodium phosphate tablet purgative and receiving propofol-based sedation."( Safety of sodium phosphate tablets in patients receiving propofol-based sedation for colonoscopy.
Eschinger, EJ; Kastenberg, DM; Katz, LC; Littman, JJ; Meyer, K; Milman, PJ,
)
0.13
" No clinically significant adverse event was detected in either group."( Safety, efficacy, and patient tolerance of a three-dose regimen of orally administered aqueous sodium phosphate for colonic cleansing before colonoscopy.
Barclay, RL, 2004
)
0.32
"Coagulation by APC is an effective and safe treatment of HRP if a complete cleansing preparation is performed to avoid explosion."( Argon plasma coagulation in the treatment of hemorrhagic radiation proctitis is efficient but requires a perfect colonic cleansing to be safe.
Antonietti, M; Ben-Soussan, E; Ducrotté, P; Herve, S; Lerebours, E; Savoye, G, 2004
)
0.32
"A systematic review of the literature was conducted to identify the most common adverse effects of sodium-phosphate enemas and associated risk factors."( Systematic review: the adverse effects of sodium phosphate enema.
Gisbert, JP; Legido, J; Mendoza, J; Rubio, S, 2007
)
0.34
" Sixty-eight per cent of the patients having adverse effects had associated conditions, the most common being gastrointestinal motility disorders, cardiological diseases and renal failure."( Systematic review: the adverse effects of sodium phosphate enema.
Gisbert, JP; Legido, J; Mendoza, J; Rubio, S, 2007
)
0.34
" Safety assessments included recording of adverse events and changes in biochemical tests and vital signs."( A randomized, multicenter study comparing the safety and efficacy of sodium phosphate tablets with 2L polyethylene glycol solution plus bisacodyl tablets for colon cleansing.
Carter, E; Cohen, LB; Forbes, WP; Johanson, JF; Lottes, SR; Popp, JW; Rose, M; Walker, K; Zhang, B, 2007
)
0.34
" The 32-tablet NaP dosing regimen was associated with fewer adverse events."( A randomized, multicenter study comparing the safety and efficacy of sodium phosphate tablets with 2L polyethylene glycol solution plus bisacodyl tablets for colon cleansing.
Carter, E; Cohen, LB; Forbes, WP; Johanson, JF; Lottes, SR; Popp, JW; Rose, M; Walker, K; Zhang, B, 2007
)
0.34
"NaP will be as safe and efficacious as polyethylene glycol (PEG) bowel preparation for colonoscopy in dogs."( Safety and efficacy of oral low-volume sodium phosphate bowel preparation for colonoscopy in dogs.
Almy, FS; Daugherty, MA; Leib, MS; Rossmeisl, JH; Ward, DL,
)
0.13
" Appropriate patient education regarding hydration and individualized patient instructions may increase compliance, reduce adverse events, promote successful bowel preparation for colonoscopy, and enhance the probability of a quality exam."( Key safety issues of bowel preparations for colonoscopy and importance of adequate hydration.
Cash, BD; Dykes, C,
)
0.13
"To compare subjective tolerance and secondary adverse events to bowel cleansing prior to colonoscopy with polyethylene glycol (PEG) and sodium phosphate (NaP) in adult patients and in those 65 or more years old."( [Tolerability, safety, and efficacy of sodium phosphate preparation for colonoscopy: the role of age].
Barreales-Valbuena, M; de la Cruz Bértolo, J; Manzano-Alonso, ML; Marín-Gabriel, JC; Rodríguez-Alcalde, D; Rodríguez-Muñoz, S; Solís-Herruzo, JA, 2008
)
0.35
" We investigated the presence of the next adverse events during bowel preparation: Fever, low digestive bleeding, abdominal pain, perianal pain, nausea, vomiting, thirst, somnolence, agitation, tremor and convulsions."( [Tolerability, safety, and efficacy of sodium phosphate preparation for colonoscopy: the role of age].
Barreales-Valbuena, M; de la Cruz Bértolo, J; Manzano-Alonso, ML; Marín-Gabriel, JC; Rodríguez-Alcalde, D; Rodríguez-Muñoz, S; Solís-Herruzo, JA, 2008
)
0.35
"Bowel cleansing prior to colonoscopy with NaP is as well tolerated, safe and effective as with PEG, even in elderly healthy patients, although it causes more nausea."( [Tolerability, safety, and efficacy of sodium phosphate preparation for colonoscopy: the role of age].
Barreales-Valbuena, M; de la Cruz Bértolo, J; Manzano-Alonso, ML; Marín-Gabriel, JC; Rodríguez-Alcalde, D; Rodríguez-Muñoz, S; Solís-Herruzo, JA, 2008
)
0.35
" Questionnaires were given to assess acceptability and adverse events."( Colon cleansing with oral sodium phosphate in adolescents: dose, efficacy, acceptability, and safety.
Barksdale, E; Di Lorenzo, C; Henderson, W; Khan, S; Sabri, M; Thompson, W, 2008
)
0.35
"5 yr and above 34 kg, 1-day oral NaP solution was more acceptable than 3-day magnesium citrate with an enema, and both regimens were found to be safe and efficacious."( Colon cleansing with oral sodium phosphate in adolescents: dose, efficacy, acceptability, and safety.
Barksdale, E; Di Lorenzo, C; Henderson, W; Khan, S; Sabri, M; Thompson, W, 2008
)
0.35
"Screening colonoscopy exposes healthy patients to the risk of serious adverse events associated with bowel preparation."( Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol.
Belsey, J; Epstein, O; Heresbach, D, 2009
)
0.35
"To search published literature in order to characterize the risk of adverse events associated with oral polyethylene glycol (PEG) or sodium phosphate (NaP)."( Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol.
Belsey, J; Epstein, O; Heresbach, D, 2009
)
0.35
" Although recent reports of adverse renal effects associated with sodium phosphate raise concern, sodium phosphate preparations remain safe and effective choices for patients who receive proper instruction for their use."( Guidelines for the safe and effective use of sodium phosphate solution for bowel cleansing prior to colonoscopy.
Balaban, DH,
)
0.13
" Food and Drug Administration and featured in the labeling of drugs associated with serious adverse reactions."( FDA boxed warnings: how to prescribe drugs safely.
O'Connor, NR, 2010
)
0.36
" All these preparations give adequate cleansing results and have similar profiles in terms of the frequency and type of mild to moderate adverse effects."( The safety of osmotically acting cathartics in colonic cleansing.
Hendel, J; Nielsen, OH; Nyberg, C, 2010
)
0.36
"These data suggest that NaP is safe and tolerable in diabetic patients, but the quality of bowel cleansing is worse than in non-diabetic patients."( Efficacy and safety of sodium phosphate for colon cleansing in type 2 diabetes mellitus.
Demir, M; Gokturk, HS; Gur, G; Ozturk, NA; Unler, GK; Yilmaz, U, 2010
)
0.36
" There was no statistical difference between the groups with regard to the adverse effects."( The efficacy and safety of colonoscopy preparation with oral sodium phosphate in elderly patients.
Bahar, K; Cetınkaya, H; Cinar, K; Seven, G; Yakut, M, 2010
)
0.36
"In the group of patients over 70 years old, a special patient group without comorbid diseases, oral sodium phosphate solution used for colon preparation was effective and well-tolerated with a low adverse effect rate."( The efficacy and safety of colonoscopy preparation with oral sodium phosphate in elderly patients.
Bahar, K; Cetınkaya, H; Cinar, K; Seven, G; Yakut, M, 2010
)
0.36
" After drug administration, a total of 15 subjects reported the occurrence of at least 1 treatment emergent adverse event (AE)."( Glycerophosphate is interchangeable with inorganic phosphate in terms of safety and serum pharmacokinetics.
Bark, S; Grossmann, M; Hochfeld, O; Joukhadar, C; Rothenburger, M; Straatsma, H; Topp, H; Westphal, M, 2011
)
0.37
" The following data were collected to determine safety and efficacy: baseline demographics, chief complaint, medical history, radiographic imaging, enema type, treatment dose, adverse effects, improvement in symptoms, time until defecation, failure of initial therapy requiring additional intervention, and time from treatment until disposition."( Safety and efficacy of milk and molasses enemas compared with sodium phosphate enemas for the treatment of constipation in a pediatric emergency department.
Darling, BE; Davis, J; Goto, CS; Hansen, SE; Quintero, CA; Whitehill, JL, 2011
)
0.37
" Based on our results, the 2 treatment options were found to be equally safe and effective."( Safety and efficacy of milk and molasses enemas compared with sodium phosphate enemas for the treatment of constipation in a pediatric emergency department.
Darling, BE; Davis, J; Goto, CS; Hansen, SE; Quintero, CA; Whitehill, JL, 2011
)
0.37
" The ideal bowel preparation agent should be efficient, safe and well tolerated by the patient."( Bowel preparation for colonoscopy: efficacy, tolerability and safety.
Bisschops, R; Martens, P, 2014
)
0.4
" Additionally, the NaP group showed better results regarding patient tolerance, satisfaction, preference, and rate of adverse events than the PEG group."( Comparison of the efficacy and safety of sodium phosphate tablets and polyethylene glycol solution for bowel cleansing in healthy Korean adults.
Kang, JK; Kim, KM; Lee, DJ; Lee, DR; Lee, EH; Lee, SH; Seo, SW, 2014
)
0.4
" Also, our study suggests that NaP tablets may be safe and can be used as a bowel cleansing agent in healthy adults undergoing elective colonoscopy."( Comparison of the efficacy and safety of sodium phosphate tablets and polyethylene glycol solution for bowel cleansing in healthy Korean adults.
Kang, JK; Kim, KM; Lee, DJ; Lee, DR; Lee, EH; Lee, SH; Seo, SW, 2014
)
0.4
" Additionally, it examines the epidemiology of adverse renal events and the safety of using sodium phosphate preparations prior to colonoscopy."( Renal risk associated with sodium phosphate medication: safe in healthy individuals, potentially dangerous in others.
Anděl, M; Hoffmanová, I; Kraml, P, 2015
)
0.42
" Despite some serious and even fatal adverse events associated with these drugs when used with at-risk patients, available data suggest that administration of sodium phosphate purgatives is relatively safe in nonrisk individuals(i."( Renal risk associated with sodium phosphate medication: safe in healthy individuals, potentially dangerous in others.
Anděl, M; Hoffmanová, I; Kraml, P, 2015
)
0.42
"The aim of this study was to examine the incidence of treatment-emergent adverse events (TEAEs) associated with SUPREP(®) [oral sulfate solution (OSS)] and other common prescription bowel preparations (non-OSS)."( A Comparative Study of Treatment-Emergent Adverse Events Following Use of Common Bowel Preparations Among a Colonoscopy Screening Population: Results from a Post-Marketing Observational Study.
Anastassopoulos, K; Cleveland, MV; Colman, S; Farraye, FA; Knight, T; Pelham, RW, 2016
)
0.43
"In actual use, the overall cumulative incidence of TEAEs was significantly lower in the OSS cohort, demonstrating that OSS is as safe as, or possibly safer than, non-OSS prescription bowel preparations."( A Comparative Study of Treatment-Emergent Adverse Events Following Use of Common Bowel Preparations Among a Colonoscopy Screening Population: Results from a Post-Marketing Observational Study.
Anastassopoulos, K; Cleveland, MV; Colman, S; Farraye, FA; Knight, T; Pelham, RW, 2016
)
0.43
" Despite reported occurrence of colonic explosion due to methane and hydrogen production by bacterial fermentation during colonoscopy, gas exchange during the procedure is believed to be effective in lowering existing methane concentration, allowing for safe utilization of mannitol for bowel preparation."( SAFETY OF MANNITOL USE IN BOWEL PREPARATION: a prospective assessment of intestinal methane (CH4) levels during colonoscopy after mannitol and sodium phosphate (NaP) bowel cleansing.
Ferrari, AP; Gonçalves, ME; Macedo, EP; Martins, FP; Paulo, GA,
)
0.13
" Our results indicate that mannitol use is as safe as NaP, and gas exchange was efficient in reducing methane concentrations."( SAFETY OF MANNITOL USE IN BOWEL PREPARATION: a prospective assessment of intestinal methane (CH4) levels during colonoscopy after mannitol and sodium phosphate (NaP) bowel cleansing.
Ferrari, AP; Gonçalves, ME; Macedo, EP; Martins, FP; Paulo, GA,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analysis has been made of plasma inorganic phosphate (Pi) in an infant after ingestion of phosphosoda laxative and of data reported for four comparable poisonings in healthy infants to provide a nomogram which predicts the decline in Pi in paediatric phosphate poisoning."( Laxative phosphate poisoning: pharmacokinetics of serum phosphorus.
Angle, CR; Larson, JE; Swigart, SA, 1986
)
0.27
"To perform a pharmacokinetic analysis of a single dose of Fleet Phospho-Soda in smaller and larger individuals."( Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis.
Ehrenpreis, ED, 2009
)
0.35
" The method was successfully applied to study the pharmacokinetic of PVP-I in rabbits after vaginal administration."( Optimization and validation of an ion-pair RP-HPLC-UV method for the determination of total free iodine in rabbit plasma: application to a pharmacokinetic study.
Cui, L; Fan, G; Wang, S; Wen, J; Zhou, T, 2009
)
0.35
"The primary aim of the present investigation was to determine and compare the pharmacokinetic (PK) profiles of inorganic phosphate in serum and urine after intravenous administration of sodium glycerophosphate and inorganic sodium phosphate."( Glycerophosphate is interchangeable with inorganic phosphate in terms of safety and serum pharmacokinetics.
Bark, S; Grossmann, M; Hochfeld, O; Joukhadar, C; Rothenburger, M; Straatsma, H; Topp, H; Westphal, M, 2011
)
0.37

Compound-Compound Interactions

ExcerptReferenceRelevance
"Two hundred and ninety-one adults scheduled for routine sigmoidoscopy were randomly assigned to receive one of three preparations containing oral magnesium citrate (296 cc) taken the night before the procedure in combination with the following: 1) oral bisacodyl (10 mg), given with the magnesium citrate the night before the procedure; 2) one hypertonic phosphate enema 1 h before the procedure; or 3) two hypertonic phosphate enemas, given singly at 2 and 1 h before the procedure."( A comparison of bowel preparations for flexible sigmoidoscopy: oral magnesium citrate combined with oral bisacodyl, one hypertonic phosphate enema, or two hypertonic phosphate enemas.
Fincher, RK; Jackson, JL; Osgard, EM; Strong, JS; Wong, RK, 1999
)
0.3
" In this communication, we have used this technique in combination with plasmids containing a tandem repeat of three 72-bp DNA elements from the SV40 enhancer to study gene expression."( Electroporation in combination with a plasmid vector containing SV40 enhancer elements results in increased and persistent gene expression in mouse muscle.
Blomberg, P; Eskandarpour, M; Islam, KB; Sylvén, C; Xia, S, 2002
)
0.31
" The aim of this study was to compare oral intake of sodium phosphate solution (SP) with a conventional method of bowel preparation using Bisacodyl combined with repeated water enemas until the appearance of clear return fluid (BE) on bowel preparation and to compare patient compliance in a randomized-investigator blinded trial."( Oral sodium phosphate compared with water enemas combined with bisacodyl as bowel preparation for elective colonoscopy.
Bohlbro, K; Qvist, N; Rasmussen, M, 2003
)
0.32
"To test if a novel dual-phase gel system (calcium silicate and phosphate with 1450 ppmF, as NaF/MFP; TG) combined with a toothpaste (calcium silicate and sodium phosphate with 1450 ppmF, as MFP; TG) was able to re-harden previously acid-challenged enamel to a greater extent than other toothpastes."( Remineralisation effect of a dual-phase calcium silicate/phosphate gel combined with calcium silicate/phosphate toothpaste on acid-challenged enamel in situ.
Gupta, AK; Joiner, A; Naeeni, MM; Schäfer, F; Zero, DT, 2014
)
0.4
"It is concluded that the test regimen based on the novel dual-phase gel system combined with toothpaste was able to re-harden acid-challenged tooth enamel to a greater extent than a normal fluoride toothpaste."( Remineralisation effect of a dual-phase calcium silicate/phosphate gel combined with calcium silicate/phosphate toothpaste on acid-challenged enamel in situ.
Gupta, AK; Joiner, A; Naeeni, MM; Schäfer, F; Zero, DT, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" It is also a rich source of Ca and P, but some research has suggested that the bioavailability of P is variable."( Bioavailability of phosphorus in meat and bone meal for swine.
Cromwell, GL; Lindemann, MD; Traylor, SL, 2005
)
0.33
"An experiment was conducted to determine the relative bioavailability (RBV) of P in high-protein sunflower meal (HP-SFM) fed to broiler chickens based on bone traits and to determine the effects of dietary phytase supplementation and increasing levels of HP-SFM as a P source on bone traits, growth performance, and apparent ileal digestibility (AID) of DM and nutrients."( Relative bioavailability of phosphorus in high-protein sunflower meal for broiler chickens and effects of dietary phytase supplementation on bone traits, growth performance, and apparent ileal digestibility of nutrients.
Kim, JW; Leterme, P; Nyachoti, CM; Sanjayan, N, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The results of this study suggest that the new rinse may provide a greater cariostatic effect at the same fluoride dosage than does a NaF rinse."( In vivo fluoride concentrations measured for two hours after a NaF or a novel two-solution rinse.
Carey, CM; Chow, LC; Mao, Y; Takagi, S; Vogel, GL, 1992
)
0.28
"0 kg) were orally dosed with 300 mg/kg FeSO4 (60 mg Fe/kg) and randomly placed into 1 of 4 treatment groups receiving 50 ml of distilled water (control), 5% sodium bicarbonate, 5% sodium dihydrogen phosphate, or deferoxamine (10 g)."( A study of iron complexation in a swine model.
Dean, B; Hines, R; Krenzelok, E; Oehme, FW, 1988
)
0.27
" Each animal group was dosed with 300 mg/kg ferrous sulfate (60 mg/kg elemental iron), followed by a 5% solution of either sodium bicarbonate, sodium dihydrogen phosphate, or a control of distilled water."( In vivo effectiveness of oral complexation agents in the management of iron poisoning.
Dean, BS; Krenzelok, EP, 1987
)
0.27
" In conclusion, in selected patients this new dosing method for sodium phosphate is preferable to large-volume, whole-gut lavage solutions."( Single-day, divided-dose oral sodium phosphate laxative versus intestinal lavage as preparation for colonoscopy: efficacy and patient tolerance.
Barnett, JL; Behler, EM; Crause, I; Elta, GH; Henderson, JM; Nostrant, TT; Turgeon, DK, 1995
)
0.29
" Patient tolerance was assessed in terms of compliance with the dosing regimen."( Efficacy and safety of sodium phosphate tablets compared with PEG solution in colon cleansing: two identically designed, randomized, controlled, parallel group, multicenter phase III trials.
Chasen, R; Choudhary, C; Kastenberg, D; Riff, D; Steinberg, S; Weiss, E; Wruble, L, 2001
)
0.31
"To evaluate the safety and efficacy of two reduced dosing regimens of sodium phosphate tablets (Visicol, InKine Pharmaceutical Co."( Safety and efficacy of two reduced dosing regimens of sodium phosphate tablets for preparation prior to colonoscopy.
Chasen, R; Pochapin, MB; Rex, DK, 2002
)
0.31
" We changed our previously reported dosing algorithm because the low dose no longer appeared to be effective at increasing serum phosphorus concentrations."( A new graduated dosing regimen for phosphorus replacement in patients receiving nutrition support.
Alexander, KH; Brown, KA; Brown, RO; Dickerson, RN; Minard, G; Morgan, LM,
)
0.13
" Patients who still had hypophosphatemia on day 2 were dosed using the new dosing algorithm by the nutrition support service according to that day's serum concentration of phosphorus, or empirically by the trauma service."( A new graduated dosing regimen for phosphorus replacement in patients receiving nutrition support.
Alexander, KH; Brown, KA; Brown, RO; Dickerson, RN; Minard, G; Morgan, LM,
)
0.13
" There was no difference in baseline characteristics among the 3 dosing groups."( A new graduated dosing regimen for phosphorus replacement in patients receiving nutrition support.
Alexander, KH; Brown, KA; Brown, RO; Dickerson, RN; Minard, G; Morgan, LM,
)
0.13
"Patients undergoing a colonoscopy received Visicol (n = 34) or 1 of 6 RF-NaP regimens administered as either split (S) dosing (the evening before and the day of colonoscopy) or evening-only (E) dosing."( Residue-free sodium phosphate tablets (OsmoPrep) versus Visicol for colon cleansing: a randomized, investigator-blinded trial.
Bernstein, J; Dalke, D; Demicco, M; Ettinger, N; Karlstadt, RG; Medoff, J; Rose, M; Safdi, A; Wruble, L; Zhang, B, 2007
)
0.34
"Split dosing with RF-NaP was associated with high OCC and achieved response rates of 90%, 97%, and 100% for 28, 32, and 40 tablets, respectively, compared with 86% for Visicol."( Residue-free sodium phosphate tablets (OsmoPrep) versus Visicol for colon cleansing: a randomized, investigator-blinded trial.
Bernstein, J; Dalke, D; Demicco, M; Ettinger, N; Karlstadt, RG; Medoff, J; Rose, M; Safdi, A; Wruble, L; Zhang, B, 2007
)
0.34
" Split dosing and 32-tablet evening-only dosing of RF-NaP tablets were efficacious and well tolerated, and split dosing of RF-NaP tablets is recommended."( Residue-free sodium phosphate tablets (OsmoPrep) versus Visicol for colon cleansing: a randomized, investigator-blinded trial.
Bernstein, J; Dalke, D; Demicco, M; Ettinger, N; Karlstadt, RG; Medoff, J; Rose, M; Safdi, A; Wruble, L; Zhang, B, 2007
)
0.34
" The effect of 1,25-dihydroxyvitamin D3 disappears when the dosing solution of phosphate is at 2 M, suggesting that 1,25-dihydroxyvitamin D3 stimulates active transport of phosphate but not diffusion of phosphate."( Characterization of intestinal phosphate absorption using a novel in vivo method.
DeLuca, HF; Williams, KB, 2007
)
0.34
" The maximum volume of drug solution absorbed was limited (2x100 microl), revealing that these porous carriers were ideal for low dosed formulations."( Porous hydroxyapatite tablets as carriers for low-dosed drugs.
Cnudde, V; Cosijns, A; Luyten, J; Masschaele, B; Mullens, S; Remon, JP; Siepmann, F; Van Hoorebeke, L; Vervaet, C, 2007
)
0.34
"The colon-cleansing efficacy of the new 32-tablet NaP dosing regimen in this study was found to be significantly better than the 2L PEG solution plus bisacodyl tablets regimen."( A randomized, multicenter study comparing the safety and efficacy of sodium phosphate tablets with 2L polyethylene glycol solution plus bisacodyl tablets for colon cleansing.
Carter, E; Cohen, LB; Forbes, WP; Johanson, JF; Lottes, SR; Popp, JW; Rose, M; Walker, K; Zhang, B, 2007
)
0.34
"To review dosing considerations and other treatment recommendations to maximize the efficacy, tolerability, and safety of sodium phosphate (NaP) preparations."( Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy.
Rex, DK, 2007
)
0.34
" In addition, accumulating clinical data and/or rationale support split dosing of NaP products, wide intervals between doses, and aggressive hydration before and during bowel preparation and after the colonoscopy procedure."( Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy.
Rex, DK, 2007
)
0.34
"Safe administration of NaP products requires rigorous attention to dosing considerations and other treatment recommendations, including administration of minimally effective doses of NaP, split-dosing schedules, and aggressive hydration."( Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy.
Rex, DK, 2007
)
0.34
"The 32-tablet sodium phosphate dosing regimen was easier to take and better tolerated, when compared to 2L polyethylene glycol plus bisacodyl tablets for bowel preparation."( Clinical trial: sodium phosphate tablets are preferred and better tolerated by patients compared to polyethylene glycol solution plus bisacodyl tablets for bowel preparation.
Forbes, WP; Grandhi, N; Lichtenstein, GR; Lottes, SR; Schmalz, M; Walker, K; Zhang, B, 2007
)
0.34
" Moreover, patient education and compliance with preparation instructions, including correct dosing and adequate hydration, may reduce the risk of adverse events and serious complications."( Bowel preparations for colonoscopy: a review.
Lichtenstein, G, 2009
)
0.35
" Clinical examination revealed persistent proteinuria from three days after the first dosing and thereafter severe proteinuria from eight days or later in the phosphate-treated groups."( Nephrotic syndrome induced by dibasic sodium phosphate injections for twenty-eight days in rats.
Matsui, T; Narama, I; Torii, M; Tsuchiya, N, 2009
)
0.35
"Using predictive Q(Ca) dosing and integrating control of the infusion pumps with the dialysis machine, SLED-RCA can be near-automated today to provide a user-friendly and safe system."( Automated regional citrate anticoagulation: technological barriers and possible solutions.
Frinak, S; Szamosfalvi, B; Yee, J, 2010
)
0.36
" Whilst there is evidence to support the ergogenic benefits of sodium phosphate, many studies researching this substance differ in terms of the administered dose and dosing protocol, the washout period employed and the fitness level of the participants recruited."( Sodium phosphate as an ergogenic aid.
Buck, CL; Dawson, B; Guelfi, KJ; Wallman, KE, 2013
)
0.39
"The solubility of inorganic calcium and phosphate in parenteral solutions can be complicated in pediatrics due to the dosing of calcium and phosphorus at the saturation point."( Physical Compatibility of Sodium Glycerophosphate and Calcium Gluconate in Pediatric Parenteral Nutrition Solutions.
Anderson, C; MacKay, M, 2015
)
0.42
"25mg/L) with a dosage of 10%."( Stabilization/solidification of lead in MSWI fly ash with mercapto functionalized dendrimer Chelator.
Li, F; Tian, Z; Wu, Y; Zhang, B; Zhao, H; Zhou, W, 2016
)
0.43
" These characteristics make isoniazid a good candidate for sustained release dosage form."( Formulation and in vitro evaluation of sustained release matrix tablets using cross-linked natural gum.
Iqbal, SM; Jamil, MN; Jamil, QA; Masood, I; Masood, MI, 2017
)
0.46
" Concurrent dosing of intravenous products via y-site administration with PN can alter the chemical balance of the solution and modify solubility."( Avoidance of Overt Precipitation and Patient Harm Following Errant Y-Site Administration of Calcium Chloride and Parenteral Nutrition Compounded With Sodium Glycerophosphate.
Anderson, C; Boehme, S; Cash, J; Stidham, C, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sodium phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)Ki780.00000.00001.372610.0000AID238512
Carbonic anhydrase 2Homo sapiens (human)Ki530.00000.00000.72369.9200AID238541
Carbonic anhydrase 4Homo sapiens (human)Ki0.08400.00021.97209.9200AID238543
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki6,870.00000.00001.27259.9000AID238514
Carbonic anhydrase 9Homo sapiens (human)Ki560.00000.00010.78749.9000AID238545
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki6,870.00000.00001.34129.9700AID238514
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID238512Inhibition constant of anion against human carbonic anhydrase isozyme hCA I2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet.
AID238545Inhibition constant of anion against human carbonic anhydrase isozyme hCA IX2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet.
AID238514Inhibition constant of anion against human carbonic anhydrase isozyme hCA V2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet.
AID238541Inhibition constant of anion against human carbonic anhydrase isozyme hCA II2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet.
AID238543Inhibition constant of anion against human carbonic anhydrase isozyme hCA IV2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,259)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990159 (12.63)18.7374
1990's215 (17.08)18.2507
2000's454 (36.06)29.6817
2010's387 (30.74)24.3611
2020's44 (3.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.37 (24.57)
Research Supply Index7.34 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials190 (14.14%)5.53%
Reviews74 (5.51%)6.00%
Case Studies138 (10.27%)4.05%
Observational6 (0.45%)0.25%
Other936 (69.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]